National Institute on Drug Abuse; Notice of Closed Meetings, 59809 [2022-21326]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 190 / Monday, October 3, 2022 / Notices
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Minority Health and Health Disparities
Special Emphasis Panel; Innovative MultiLevel Approaches and Strategies to Prevent,
Test, and Treat HIV in HDP.
Date: November 14, 2022.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Gateway Plaza, 7201 Wisconsin Ave.,
Bethesda, MD 20817 (Virtual Meeting).
Contact Person: Ivan K. Navarro, Ph.D.,
Scientific Review Officer, Office of
Extramural Research Administration,
National Institute on Minority Health and
Health Disparities, National Institutes of
Health, Gateway Building, 7201 Wisconsin
Avenue, Bethesda, MD 20892, 301–827–
2061, ivan.navarro@nih.gov.
Dated: September 27, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–21358 Filed 9–30–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
VerDate Sep<11>2014
19:00 Sep 30, 2022
Jkt 259001
Exploiting in Vivo or in Situ Imaging
Approaches to Understand HIV-relevant
Processes in the Context of Substance Use
Disorders.
Date: October 24, 2022.
Time: 12 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Jenny Raye Browning,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443–4577,
jenny.browning@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA K
Conflict SEP.
Date: November 2, 2022.
Time: 11 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Marisa Srivareerat, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 435–1258,
marisa.srivareerat@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Avant-Garde Award Program and Avenir
Award Program for Research on Substance
Use Disorders and HIV/AIDS.
Date: December 2, 2022.
Time: 10 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sheila Pirooznia, Ph.D.,
Scientific Review Officer, Division of
Extramural Review, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 496–9350,
sheila.pirooznia@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: September 27, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–21326 Filed 9–30–22; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
59809
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Applied Immunology
and Disease Control Integrated Review
Group; Drug Discovery and Mechanisms of
Antimicrobial Resistance Study Section.
Date: November 1–2, 2022.
Time: 8:30 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: DoubleTree Tysons, 1960 Chain
Bridge Road, McLean, VA 22101.
Contact Person: Bidyottam Mittra, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20894, (301) 435–0000, bidyottam.mittra@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Cell Biology, Developmental
Biology and Bioengineering.
Date: November 1–2, 2022.
Time: 9:30 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health
Rockledge II 6701 Rockledge Drive Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Alexander Gubin, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4196,
MSC 7812, Bethesda, MD 20892, 301–435–
2902, gubina@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Disease Management, Risk
Prevention, and Health Behavior Change.
Date: November 1–2, 2022.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jennifer Di Noia, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1000E,
E:\FR\FM\03OCN1.SGM
03OCN1
]]>Agencies
[Federal Register Volume 87, Number 190 (Monday, October 3, 2022)]
[Notices]
[Page 59809]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-21326]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Exploiting in Vivo or in Situ Imaging Approaches to
Understand HIV-relevant Processes in the Context of Substance Use
Disorders.
Date: October 24, 2022.
Time: 12 p.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Jenny Raye Browning, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 443-4577,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA K Conflict SEP.
Date: November 2, 2022.
Time: 11 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Marisa Srivareerat, Ph.D., Scientific Review
Officer, Scientific Review Branch, Office of Extramural Policy,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 435-1258,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA Avant-Garde Award Program and Avenir Award
Program for Research on Substance Use Disorders and HIV/AIDS.
Date: December 2, 2022.
Time: 10 a.m. to 6 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sheila Pirooznia, Ph.D., Scientific Review
Officer, Division of Extramural Review, Scientific Review Branch,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 496-9350,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 27, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-21326 Filed 9-30-22; 8:45 am]
BILLING CODE 4140-01-P
